A class of type 2 diabetes medications called SGLT2 inhibitors doubles the risk of developing the life threatening condition ketoacidosis, according to a study published in the New England Journal of Medicine. The findings arose from the largest study to date investigating whether SGLT2 inhibitors, such as the widely prescribed Invokana, increase the risk of diabetic ketoacidosis, or DKA. It was conducted by researchers with the Brigham and Women’s Hospital in Boston, Massachusetts. Researchers put the risk of developing DKA at between 5 and 8 per 1,000 for new users of SGLT2 inhibitors. “We found a doubling in the risk ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.